A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
NCT #
NCT05503797
Condition(s)
Central Nervous System Tumor, GBM (Glioblastoma)
Molecular Target(s)
BRAF
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
solid tumor
Phase(s)
II
Mechanism of Action
n/a
Purpose
n/a
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.